5 Best Diagnostics and Research Stocks to Buy According to Analysts

4. Agilent Technologies, Inc. (NYSE:A)

Number of Hedge Fund Holders: 71

Agilent Technologies, Inc. (NYSE:A) is one of the 10 best diagnostics and research stocks to buy according to analysts.

On March 9, 2026, Agilent Technologies, Inc. (NYSE:A) announced entering into a definitive agreement to acquire Biocare Medical for $950 million. The all-cash deal combines Biocare’s high-growth portfolio of immunohistochemistry (IHC) antibodies and reagents with Agilent Technologies, Inc. (NYSE:A)’s existing pathology division. Biocare has consistently generated double-digit revenue growth since 2021. In 2025, it generated over $90 million in revenue. Agilent Technologies, Inc. (NYSE:A) anticipates the acquisition to be immediately accretive to its revenue mix and margins, adding strength to the company’s competitive position in cancer diagnostics and clinical research. The transaction is anticipated to close by late 2026.

In another development, the company announced the launch of Agilent Advanced Therapeutics on March 11, 2026. This unified Contract Development and Manufacturing Organization (CDMO) integrates the company’s Canadian BIOVECTRA with Colorado’s Nucleic Acid Solutions and offers end-to-end services for oligonucleotides and APIs in addition to cell line development. Padraig McDonnell, President and CEO of Agilent Technologies, Inc. (NYSE:A) stated that the launch supports the company’s long-term commitment to growth in the sector.

Founded in 1999, Agilent Technologies, Inc. (NYSE:A) is a global leader in life sciences, diagnostics, and applied chemical markets with headquarters in California.